top of page

CURRENT RESEARCH STUDIES

If you are interested in participating in a research study, please send

an email to research@ranchoresearch.org with the following information:

Full Name:

Contact Number:

Email Address:

Briefly explain your motivation to participate:

 

Alternatively, you can call our office at (562) 385-8111 during regular business hours to

express your interest and provide the necessary details over the phone.

arrow&v
arrow&v
arrow&v
arrow&v

Indication:

Chronic kidney disease

Trial Name:

GKPTN

Description:

A Prospective International Multi-Centre, Observational Cohort Study of Incident and Prevalent Patients Diagnosed with a Kidney Disease

Contact:

(562) 385-7463

Investigator:

Nina Patel, MD

Sponsor:

The George Clinical Institute for Global Health

Funding:

Industry

Indication:

Chronic kidney disease

Trial Name:

ZENITH

Description:

A Phase 2b Multicentre, Randomised, Double-Blind, Placebo- Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with an eGFF Between 20 and 60 mL/min/1.73 m2

Contact:

(562) 385-7463

Investigator:

Nina Patel, MD

Sponsor:

AstraZeneca

Funding:

Industry

Indication:

Chronic kidney disease-related hyperkalemia and metabolic acidosis

Trial Name:

NEUTRALIZE

Description:

A Double-blind Randomized Placebo-controlled Parallel Design Multicenter Phase IIIb Study of the Effect of Sodium Zirconium Cyclosilicate (SZC) on Serum Potassium and Serum Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease

Contact:

(562) 385-7020

Investigator:

Nina Patel, MD

Sponsor:

AstraZeneca

Funding:

Industry

Indication:

Diabetic foot ulcers

Trial Name:

NuShield

Description:

A Phase 3, Prospective, Multicenter, Randomized, Controlled Clinical Study of NuShield® and Standard of Care (SOC) Compared to SOC Alone for the Management of Diabetic Foot Ulcers

Contact:

(562) 385-6201

Investigator:

David Armstrong, DPM

Sponsor:

Organogenesis Inc.

Funding:

Industry

Indication:

Epilepsy

Trial Name:

Illuminate

Description:

A Phase 4, Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated with Epidiolex (Cannabidiol) Oral Solution

Contact:

(562) 385-7020

Investigator:

Hui Gong, MD

Sponsor:

GW Research LTD

Funding:

Industry

Indication:

Epilepsy

Trial Name:

RAISE

Description:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IV Ganaxolone in RSE Patients Who Have Failed Benzodiazepines and Two or More Second Line Intravenous Antiepileptic Drugs (AEDs)

Contact:

(562) 385-7020

Investigator:

Susan Shaw, MD

Sponsor:

Marinus Pharmacetuticals

Funding:

Industry

Indication:

Polycystic kidney disease

Trial Name:

FALCON

Description:

A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease

Contact:

(562) 385-7048

Investigator:

Nina Patel, MD

Sponsor:

Reata Pharmaceuticals

Funding:

Industry

Indication:

Spinal cord injury-related urinary bladder dysfunction and incontinenece

Trial Name:

Bladder Stim

Description:

The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life after Acute Traumatic Spinal Cord Injury

Contact:

(562) 385-6201

Investigator:

David Ginsberg, MD

Sponsor:

University of Utah

Funding:

Industry

Indication:

Stroke rehabilitation

Trial Name:

FitMi Plus

Description:

FitMi Plus: Smart Functional Modules for Practicing Activities of Daily Living after Stroke

Contact:

(562) 385-7463

Investigator:

Susan Shaw, MD

Sponsor:

Flint Rehab

Funding:

Industry

Indication:

Stroke- or TBI-related lower extremity spasticity

Trial Name:

ABOLISH

Description:

A Phase 4 International, Multicentre, Observational, Prospective, Longitudinal Study to Assess the effectiveness of ABOBONT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort

Contact:

(562) 385-7048

Investigator:

Ziyad Ayyoub, MD

Sponsor:

Ipsen

Funding:

Industry

Indication:

Stroke- or TBI-related lower extremity spasticity

Trial Name:

PHLEX-LOW

Description:

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of a Single-Dose of MYOBLOC in Adult Subjects with Lower Limb Monoplegia or Hemiplegia Spasticity Due to Stroke or TBI, Followed by an Open-Label Extension Safety Study of Multiple Doses

Contact:

(562) 385-7048

Investigator:

Ziyad Ayyoub, MD

Sponsor:

Supernus Pharmaceuticals

Funding:

Industry

Indication:

Stroke- or TBI-related upper extremity spasticity

Trial Name:

DIRECTION

Description:

A Phase 4 Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity

Contact:

(562) 385-7048

Investigator:

Ziyad Ayyoub, MD

Sponsor:

Ipsen

Funding:

Industry

Indication:

Stroke- or TBI-related upper extremity spasticity

Trial Name:

PHLEX-UP

Description:

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOC®

Contact:

(562) 385-7048

Investigator:

Ziyad Ayyoub, MD

Sponsor:

Supernus Pharmaceuticals

Funding:

Industry

Indication:

Ulcers of the lower extremity

Trial Name:

AnGes

Description:

A Phase 2 Double-Blind, Randomized, Placebo-Bontrolled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity

Contact:

(562) 385-6201

Investigator:

David Armstrong, DPM

Sponsor:

AnGes USA Inc.

Funding:

Industry

Indication:

Users of long-term indwelling catheters

Trial Name:

Silq

Description:

A Phase 4, Prospective, Multi-center, Randomized Study to Assess the Ability of the Silq ClearTract Urinary Catherter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-Coated Latex)

Contact:

(562) 385-6201

Investigator:

Evgeniy Kreydin, MD

Sponsor:

Silq Technologies Corporation

Funding:

Industry

bottom of page